EUCTR2021-003889-12-ESActive, not recruitingPhase 1
Prospective, multicenter and open study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus and cardiotoxic treatments. - CIBER-bB-ECHO
Consorcio Centro de Investigacion Biomedica en Red, M.P. (CIBER)0 sites1,000 target enrollmentStarted: December 3, 2021Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 1,000
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Age = 18 years.
- •- Absence of previous heart disease, defined as the absence of relevant cardiac structural alterations such as moderate or severe hypertrophy, alteration of segmental contraction, Moderate or severe valvular disease, intraventricular obstructive gradient, or old myocardial infarction.
- •- Existence of an at least acceptable ultrasonic window, which allows the visualization of at least 14 of the 17 segments of the LV myocardium.
- •- Sinus rhythm, with a basal heart rate greater than 50 bpm.
- •- Diabetic patients with a diagnosis of DM2 with or without HFNEF (n = 300) will be included. Previous diagnosis of HFNEF with clinical stability at the time of inclusion (n = 200). No previous diagnosis of HFNEF (n = 100).
- •- 200 patients with cirrhosis stratified by the following additional criteria will be included: Child-Pugh A class (n = 25); Child-Pugh B class (n = 75); Child-Pugh C class (with and without ascites n = 50 and n = 50, respectively).
- •- 300 cancer patients will be included, divided into 3 therapeutic groups: 125 patients diagnosed with Lymphoma or Sarcoma receiving chemotherapy based on anthracyclines at high doses (= 240 mg / m2); 125 patients with HER2 positive breast cancer receiving chemotherapy regimen that includes trastuzumab without anthracyclines; 50 patients with hepatocarcinoma receiving treatment with Sorafenib.
- •- Expected survival> 6 months, first-diagnosis of cancer, and receiving treatment with chemotherapy that includes any of the previous schemes.
- •- A control group (n = 200) without heart disease and without any of the study conditions will be included: diabetes from any cause, cancer or active cancer treatment or some degree of liver disease.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 800
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
Exclusion Criteria
- •- Contraindication for the administration of esmolol (according to technical data sheet): Hypersensitivity to esmolol hydrochloride; Severe sinus bradycardia (HR <50 bpm); 2nd or 3rd degree atrioventricular block without pacemaker; Cardiogenic shock, severe hypotension, or decompensated heart failure; Untreated pheochromocytoma; Acute asthmatic attack; Concomitant intravenous administration or within the first 48 hours after verapamil.
- •- Treatment with beta-blocker drugs (oral, topical or intravenous) in the last 7 days before the study.
- •- History of ventricular or supraventricular arrhythmias that prevent the safe withdrawal of antiarrhythmic or braking treatment before the administration of esmolol.
- •- History of previous high-grade AV conduction disorder in non-pacemaker patients.
- •- Severe asthma with bronchial hyperresponsiveness.
- •- Patients with acute infection.
- •- Participants in other clinical trials in the 30 days prior to the start of the study.
- •- Pregnant women, or who plan to be, and women during breastfeeding.
- •- Patients with limitation to follow the protocol for any reason.
- •- Diagnosis of DM of any type other than type 2 (type 1, LADA, MODY, NODAT, etc.).
- •- Patients in NYHA functional class IV or with advanced heart failure.
- •- Treatment with an oral beta-blocker at the time of the examination that cannot be safely temporarily suspended 72 hours before the test.
- •- Active evidence of HBV or HCV infection.
- •- Personal history of previous cancer requiring systemic treatment (excludes skin or localized cancers treated locally surgically).
- •- Previous exposure to systemic antitumor treatment or radiotherapy on the thoracic region.
Investigators
Similar Trials
Completed
Phase 4
A clinical trial to assess the confidence, usability, preference and satisfaction on use of Dry Powder Inhaler (DPI) in healthy volunteers and in subjects with mild asthma or COPD.CTRI/2009/091/000215Cipla Ltd100
Active, not recruiting
Not Applicable
A multicentre, open, prospective study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT681 in patients with primary immunodeficiency disease (PID)primary immunodeficiency syndrome as congenital agammaglobulinaemia or hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiencies, Wiskott Aldrich syndromeMedDRA version: 7.0Level: HLTClassification code 10036700EUCTR2004-004465-15-HUBiotest AG50
Active, not recruiting
Not Applicable
A multicentre, open, prospective study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT681 in patients with primary immunodeficiency disease (PID)primary immunodeficiency syndrome as congenital agammaglobulinaemia or hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiencies, Wiskott Aldrich syndromeMedDRA version: 7.0Level: HLTClassification code 10036700EUCTR2004-004465-15-DEBiotest AG50
Active, not recruiting
Not Applicable
Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent &#946;-thalassemic patients with cardiac MRI T2* <20 msec - NDcardiac iron overloadMedDRA version: 9.1Level: LLTClassification code 10019024Term: HaemosiderosisEUCTR2008-003230-22-ITOVARTIS FARMA
Not yet recruiting
Phase 4
A prospective, multicenter, randomized, open study on the efficacy and safety of Yisaipu combined with traditional Chinese medicine for standard treatment and maintenance therapy in RA patients who failed traditional DMARDs treatmentRheumatoid arthritisITMCTR1900002628Guang'anmen Hospital, China Academy of Chinese Medical Sciences